{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:04:20Z","timestamp":1790157860652,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["14-24-00086"],"award-info":[{"award-number":["14-24-00086"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00403-017-1738-z","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T11:39:56Z","timestamp":1492688396000},"page":"433-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas"],"prefix":"10.1007","volume":"309","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9885-9056","authenticated-orcid":false,"given":"K. A.","family":"Rubina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Yu.","family":"Sysoeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. I.","family":"Zagorujko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. I.","family":"Tsokolaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"Kurdina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye. V.","family":"Parfyonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. A.","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"issue":"2","key":"1738_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1871525712666141106095927","volume":"12","author":"RA Al-Horani","year":"2014","unstructured":"Al-Horani RA (2014) Serpin regulation of fibrinolytic system; implications for applications in cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 12(2):91\u2013125","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"1738_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z","volume":"72","author":"PA Andreasen","year":"1997","unstructured":"Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activation system in cancer metastasis; a review. Int J Cancer 72:1\u201322","journal-title":"Int J Cancer"},{"key":"1738_CR3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0140-6736(91)90357-U","volume":"338","author":"JNWN Barker","year":"1991","unstructured":"Barker JNWN (1991) Pathophysiology of psoriasis. Lancet 338:227\u2013230","journal-title":"Lancet"},{"key":"1738_CR4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1046\/j.1365-2133.1999.03205.x","volume":"141","author":"M Bhushan","year":"1999","unstructured":"Bhushan M, Mclaughlin B, Weiss JB (1999) Level of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054\u20131060","journal-title":"Br J Dermatol"},{"key":"1738_CR5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.104.4.801","volume":"104","author":"F Blasi","year":"1987","unstructured":"Blasi F, Vassalli J-D, Dano K (1987) Urokinase-type plasminogen activator; proenzyme, receptor, and inhibitors. J Cell Biol 104:801\u2013804","journal-title":"J Cell Biol"},{"key":"1738_CR6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrm977","volume":"3","author":"F Blasi","year":"2002","unstructured":"Blasi F, Carmeliet P (2002) uPAR; a versatile signaling orchestrator. Nat Rev Mol Cell Biol 3:932\u2013943","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"1738_CR7","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/j.febslet.2009.12.039","volume":"584","author":"F Blasi","year":"2010","unstructured":"Blasi F, Sidenius N (2010) The urokinase receptor; focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584(9):1923\u20131930","journal-title":"FEBS Lett"},{"key":"1738_CR8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0046-8177(95)90276-7","volume":"26","author":"L Buo","year":"1995","unstructured":"Buo L, Meling GI, Karlsrud TS (1995) Antigen level of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 26:1133\u20131138","journal-title":"Hum Pathol"},{"issue":"2","key":"1738_CR9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1523-1747.ep12340609","volume":"106","author":"CS Chen","year":"1996","unstructured":"Chen CS, Jensen PJ (1996) Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression. J Investig Dermatol 106(2):238\u2013242","journal-title":"J Investig Dermatol"},{"key":"1738_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0190-9622(03)01136-8","volume":"49","author":"J Choi","year":"2003","unstructured":"Choi J, Koo JY (2003) Quality of life issues in psoriasis. J Am Acad Dermatol 49:57\u201361","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1738_CR11","first-page":"259","volume":"82","author":"D Collen","year":"1999","unstructured":"Collen D (1999) The plasminogen (fibrinolytic) system. Thromb Haemost 82(2):259\u2013270","journal-title":"Thromb Haemost"},{"issue":"1","key":"1738_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2001.1.1","volume":"1","author":"D Collen","year":"2001","unstructured":"Collen D (2001) Role of the plasminogen system in fibrin-homeostasis and tissue remodelling. Hematology 1(1):1\u20139","journal-title":"Hematology"},{"key":"1738_CR13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1160\/TH10-01-0017","volume":"104","author":"RW Colman","year":"2010","unstructured":"Colman RW, Wu Y, Liu Y (2010) Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signaling. Thromb Haemost 104:875\u2013885","journal-title":"Thromb Haemost"},{"key":"1738_CR14","first-page":"1661","volume":"147","author":"D Creamer","year":"1995","unstructured":"Creamer D, Allen M, Sousa A (1995) Altered vascular endothelium integrin expression in psoriasis. Am J Pathol 147:1661\u20131667","journal-title":"Am J Pathol"},{"key":"1738_CR15","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1111\/j.1365-2133.1997.tb01543.x","volume":"137","author":"D Creamer","year":"1997","unstructured":"Creamer D, Jaggar M, Allen M (1997) Overexpression of angiogenic growth factor platelet-derived endothelial cell growth factor\/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 137:8851\u20138855","journal-title":"Br J Dermatol"},{"key":"1738_CR16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1024515517623","volume":"5","author":"D Creamer","year":"2002","unstructured":"Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231\u2013236","journal-title":"Angiogenesis"},{"key":"1738_CR17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.180.3.1141","volume":"180","author":"M Detmar","year":"1994","unstructured":"Detmar M, Brown LF, Claffey KP (1994) Overexpression of vascular permeability factor\/vascular endothelial growth factor and its receptor in psoriasis. J Exp Med 180:1141\u20131146","journal-title":"J Exp Med"},{"issue":"4","key":"1738_CR18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13058-014-0428-4","volume":"16","author":"MJ Duffy","year":"2014","unstructured":"Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M (2014) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16(4):428","journal-title":"Breast Cancer Res"},{"key":"1738_CR19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.2916128","volume":"243","author":"JT Elder","year":"1989","unstructured":"Elder JT, Fisher GJ, Lindquist PB (1989) Overexpression of transforming growth factor-a in psoriatic epidermis. Science 243:811\u2013814","journal-title":"Science"},{"key":"1738_CR20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","volume":"96","author":"P Ettehadi","year":"1994","unstructured":"Ettehadi P, Greaves MW, Wallach D (1994) Elevated tumor necrosis factor-a (TNF-a) biological activity in psoriatic lesions. Clin Exp Immunol 96:146\u2013151","journal-title":"Clin Exp Immunol"},{"key":"1738_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13005-016-0106-0","volume":"12","author":"L Feller","year":"2016","unstructured":"Feller L, Khammissa RA, Kramer B, Altini M, Lemmer J (2016) Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med 12:11","journal-title":"Head Face Med"},{"key":"1738_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2133.1983.tb04577.x","volume":"108","author":"JE Fraki","year":"1983","unstructured":"Fraki JE, Lazarus GS, Gilgor RS, Marchase P, Singer KH (1983) Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. Br J Dermatol 108:39\u201344","journal-title":"Br J Dermatol"},{"issue":"2","key":"1738_CR23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4330\/wjc.v8.i2.120","volume":"8","author":"G Ganzetti","year":"2016","unstructured":"Ganzetti G, Campanati A, Molinelli E, Offidani A (2016) Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background. World J Cardiol 8(2):120\u2013131","journal-title":"World J Cardiol"},{"issue":"1","key":"1738_CR24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2249.1996.d01-802.x","volume":"106","author":"A Gilhar","year":"1996","unstructured":"Gilhar A, David M, Kalish RS, Weisinger G (1996) In vivo effects of cytokines on psoriatic skin grafted on nude mice; involvement of the tumour necrosis factor (TNF) receptor. Clin Exp Immunol 106(1):134\u2013142","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"1738_CR25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2133.1993.tb00254.x","volume":"128","author":"HM Gissler","year":"1993","unstructured":"Gissler HM, Frank R, Kramer MD (1993) Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. Br J Dermatol 128(6):612\u2013618","journal-title":"Br J Dermatol"},{"issue":"2","key":"1738_CR26","first-page":"50","volume":"13","author":"A Godi","year":"2004","unstructured":"Godi A (2004) New approaches to psoriasis treatment. Acta Dermatovenerol 13(2):50\u201357","journal-title":"Acta Dermatovenerol"},{"key":"1738_CR27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.thromres.2009.11.034","volume":"125","author":"MW Gramling","year":"2010","unstructured":"Gramling MW, Church FC (2010) Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 125:377\u2013381","journal-title":"Thromb Res"},{"issue":"3","key":"1738_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2133.1985.tb02076.x","volume":"113","author":"J Grondahl-Hansen","year":"1985","unstructured":"Grondahl-Hansen J, Nielsen LS, Kristensen P, Grondahl-Hansen V, Andreasen PA, Dano K (1985) Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 113(3):257\u2013263","journal-title":"Br J Dermatol"},{"issue":"1","key":"1738_CR29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/1523-1747.ep12464827","volume":"88","author":"J Grondahl-Hansen","year":"1987","unstructured":"Grondahl-Hansen J, Ralfkiaer E, Nielsen LS, Kristensen P, Frentz G, Dano K (1987) Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Investig Dermatol 88(1):28\u201332","journal-title":"J Investig Dermatol"},{"issue":"5","key":"1738_CR30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3816\/CBC.2004.n.040","volume":"5","author":"N Harbeck","year":"2004","unstructured":"Harbeck N, Kates RE, Schmitt M (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5(5):348\u2013352","journal-title":"Clin Breast Cancer"},{"issue":"24","key":"1738_CR31","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1007\/s00018-015-2035-7","volume":"72","author":"B Heissig","year":"2015","unstructured":"Heissig B, Dhahri D, Eiamboonsert S, Salama Y, Shimazu H, Munakata S, Hattori K (2015) Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression. Cell Mol Life Sci 72(24):4759\u20134770","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1738_CR32","first-page":"15","volume":"34","author":"R Hildenbrand","year":"2009","unstructured":"Hildenbrand R, Schaaf A (2009) The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 34(1):15\u201323","journal-title":"Int J Oncol"},{"key":"1738_CR33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00002281-200107000-00005","volume":"13","author":"T Hohler","year":"2001","unstructured":"Hohler T, Marker-Hermann E (2001) Psoriatic arthritis; clinical aspects, genetics and the role of T-cells. Curr Opin Rheumatol 13:273\u2013279","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"1738_CR34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/1523-1747.ep12461494","volume":"90","author":"PJ Jensen","year":"1988","unstructured":"Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS (1988) Epidermal plasminogen activator is abnormal in cutaneous lesions. J Investig Dermatol 90(6):777\u2013782","journal-title":"J Investig Dermatol"},{"issue":"5","key":"1738_CR35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/1523-1747.ep12505666","volume":"95","author":"PJ Jensen","year":"1990","unstructured":"Jensen PJ, Baird J, Belin D, Vassalli JD, Busso N, Gubler P, Lazarus GS (1990) Tissue plasminogen activator in psoriasis. J Investig Dermatol 95(5):13\u201314","journal-title":"J Investig Dermatol"},{"issue":"5","key":"1738_CR36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/DSS.0000000000000296","volume":"41","author":"AN Kauvar","year":"2015","unstructured":"Kauvar AN, Cronin T Jr, Roenigk R, Hruza G, Bennett R (2015) Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 41(5):550\u2013571","journal-title":"Dermatol Surg"},{"key":"1738_CR37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1747.2001.01316.x","volume":"116","author":"K Kuroda","year":"2001","unstructured":"Kuroda K, Sapadin A, Shoji T (2001) Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Investig Dermatol 116:713\u2013720","journal-title":"J Investig Dermatol"},{"issue":"5","key":"1738_CR38","first-page":"26","volume":"9","author":"J Lanoue","year":"2016","unstructured":"Lanoue J, Goldenberg G (2016) Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies. J Clin Aesthet Dermatol 9(5):26\u201336","journal-title":"J Clin Aesthet Dermatol"},{"key":"1738_CR39","unstructured":"Leurer C, Rabbani SA (2015) Plasminogen activator system\u2014diagnostic, prognostic and therapeutic implications in breast cancer, a concise review of molecular pathology of breast cancer. In: Gunduz M (ed) A concise review of molecular pathology of breast cancer. ISBN 978-953-51-2030-8"},{"issue":"5","key":"1738_CR40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","volume":"166","author":"A Lomas","year":"2012","unstructured":"Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 166(5):1069\u20131080","journal-title":"Br J Dermatol"},{"key":"1738_CR41","first-page":"36","volume":"146","author":"T Lotti","year":"1989","unstructured":"Lotti T, Bonan P, Panconesi E (1989) Plasminogen activation in psoriasis. Acta Derm Venereol Suppl (Stockh) 146:36\u201338","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"7","key":"1738_CR42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-4362.1990.tb04853.x","volume":"29","author":"T Lotti","year":"1990","unstructured":"Lotti T, Bonan P, Cannarozzo G, Fedi AM, Panconesi E (1990) Antipsoriatic therapies inhibit epidermal plasminogen activator activity. Int J Dermatol 29(7):528\u2013530","journal-title":"Int J Dermatol"},{"key":"1738_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9831237","author":"M Lupu","year":"2016","unstructured":"Lupu M, Caruntu C, Ghita MA, Voiculescu V, Voiculescu S, Rosca AE, Caruntu A, Moraru L, Popa IM, Calenic B, Greabu M, Costea DE (2016) Gene expression and proteome analysis as sources of biomarkers in basal cell carcinoma. Dis Mark. doi: 10.1155\/2016\/9831237","journal-title":"Dis Mark"},{"issue":"2","key":"1738_CR44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00269356","volume":"101","author":"B Lyons-Giordano","year":"1994","unstructured":"Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ (1994) Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 101(2):105\u2013112","journal-title":"Histochemistry"},{"key":"1738_CR45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<457::AID-IJC2>3.0.CO;2-6","volume":"85","author":"T Maguire","year":"2000","unstructured":"Maguire T, Chin D, Soutar D, Duffy MJ (2000) Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. Int J Cancer 85:457\u2013459","journal-title":"Int J Cancer"},{"key":"1738_CR46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/A:1009095825561","volume":"3","author":"AP Mazar","year":"1999","unstructured":"Mazar AP, Henkin J, Goldfarb RH (1999) The urokinase plasminogen activator system in cancer; implication for tumor angiogenesis and metastasis. Angiogenesis 3:15\u201332","journal-title":"Angiogenesis"},{"issue":"22","key":"1738_CR47","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1158\/0008-5472.CAN-15-0378","volume":"75","author":"R Mazzieri","year":"2015","unstructured":"Mazzieri R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, Danese S, Mignatti P, Blasi F, D\u2019Alessio S (2015) Urokinase receptor promotes skin tumor formation by preventing epithelial cell activation of notch. Cancer Res 75(22):4895\u20134909","journal-title":"Cancer Res"},{"issue":"3","key":"1738_CR48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/1523-1747.ep12499803","volume":"98","author":"SJ Miller","year":"1992","unstructured":"Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS (1992) Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Investig Dermatol 98(3):351\u2013358","journal-title":"J Investig Dermatol"},{"key":"1738_CR49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ijc.2910190504","volume":"19","author":"B Nagy","year":"1977","unstructured":"Nagy B, Ban J, Brdar B (1977) Fibrinolysis associated with human neoplasia; production of plasminogen activators by human tumors. Int J Cancer 19:614\u2013620","journal-title":"Int J Cancer"},{"key":"1738_CR50","first-page":"820","volume":"144","author":"BJ Nickoloff","year":"1994","unstructured":"Nickoloff BJ, Mitra RS, Varani J (1994) Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144:820\u2013828","journal-title":"Am J Pathol"},{"key":"1738_CR51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1087-0024.2000.00006.x","volume":"5","author":"BJ Nickoloff","year":"2000","unstructured":"Nickoloff BJ (2000) Characterization of lymphocyte-dependent angiogenesis using a SCID mouse; Human skin model of psoriasis. J Investig Dermatol 5:67\u201373","journal-title":"J Investig Dermatol"},{"issue":"11","key":"1738_CR52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/PL00012428","volume":"51","author":"HJ Nielsen","year":"2002","unstructured":"Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brunner N, Petersen LJ, Kristensen JK (2002) Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51(11):563\u2013567","journal-title":"Inflamm Res"},{"issue":"1","key":"1738_CR53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1013964517211","volume":"67","author":"YV Parfyonova","year":"2002","unstructured":"Parfyonova YV, Plekhanova OS, Tkachuk VA (2002) Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Moscow) 67(1):139\u2013156","journal-title":"Biochemistry (Moscow)"},{"issue":"7","key":"1738_CR54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.18565\/cardio.2015.7.63-77","volume":"55","author":"OS Plekhanova","year":"2015","unstructured":"Plekhanova OS, Parfenova EV, Tkachuk VA (2015) Mechanisms of vascular remodeling following arterial injury. Kardiologiia 55(7):63\u201377","journal-title":"Kardiologiia"},{"key":"1738_CR55","volume-title":"Rook\u2019s textbook of dermatology","author":"AG Quinn","year":"2010","unstructured":"Quinn AG, Perkins W (2010) Non-melanoma skin cancer and other epidermal skin tumors. In: Burns T, Breathnach S, Cox N, Griffiths C (eds) Rook\u2019s textbook of dermatology. Blackwell Publishing Ltd, Chichester"},{"issue":"10","key":"1738_CR56","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2012","unstructured":"Rogers HW, Weinstock MA, Feldman SR, Coldiron BM (2012) Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population. JAMA Dermatol 151(10):1081\u20131086","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1738_CR57","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF02505254","volume":"288","author":"JM Rox","year":"1996","unstructured":"Rox JM, Reinartz J, Kramer MD (1996) Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). Arch Dermatol Res 288(9):554\u2013558","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1738_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0148450","volume":"11","author":"J Ruano","year":"2016","unstructured":"Ruano J, Su\u00e1rez-Fari\u00f1as M, Shemer A, Oliva M, Guttman-Yassky E, Krueger JG (2016) Molecular and cellular profiling of scalp psoriasis reveals differences and similarities compared to skin psoriasis. PloS One 11(2):1\u201318","journal-title":"PloS One"},{"key":"1738_CR59","volume-title":"Transforming growth factor-beta and urokinase-type plasminogen activator; dangerous partners in tumorigenesis. implications in skin cancer volume","author":"JF Santibanez","year":"2013","unstructured":"Santibanez JF (2013) Transforming growth factor-beta and urokinase-type plasminogen activator; dangerous partners in tumorigenesis. implications in skin cancer volume. Hindawi Publishing Corporation, UK, ISRN Dermatology. Article ID 597927"},{"issue":"4","key":"1738_CR60","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1172\/JCI115406","volume":"88","author":"AP Sappino","year":"1991","unstructured":"Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD (1991) Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Investig 88(4):1073\u20131079","journal-title":"J Clin Investig"},{"issue":"1","key":"1738_CR61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1657541","volume":"78","author":"M Schmitt","year":"1997","unstructured":"Schmitt M, Harbeck N, Thompson C (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis; prognostic relevance and target for therapy. Thromb Hemost 78(1):285\u2013296","journal-title":"Thromb Hemost"},{"issue":"8","key":"1738_CR62","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1586\/erm.10.71","volume":"10","author":"M Schmitt","year":"2010","unstructured":"Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A (2010) Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 10(8):1051\u20131067","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"1738_CR63","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jso.10210","volume":"82","author":"DQ Seetoo","year":"2003","unstructured":"Seetoo DQ, Crowe PJ, Russell PJ, Yang JL (2003) Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 82(3):184\u2013193","journal-title":"J Surg Oncol"},{"issue":"3","key":"1738_CR64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/1523-1747.ep12371792","volume":"102","author":"EM Spiers","year":"1994","unstructured":"Spiers EM, Lazarus GS, Lyons-Giordano B (1994) Expression of plasminogen activator enzymes in psoriatic epidermis. J Investig Dermatol 102(3):333\u2013338","journal-title":"J Investig Dermatol"},{"key":"1738_CR65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9896(199603)178:3<290::AID-PATH472>3.0.CO;2-4","volume":"178","author":"EM Spiers","year":"1996","unstructured":"Spiers EM, Lazarus GS, Lyons-Giordano B (1996) Expression of plasminogen activators in basal cell carcinoma. J Pathol 178:290\u2013296","journal-title":"J Pathol"},{"issue":"2","key":"1738_CR66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000211410","volume":"9","author":"P Teofoli","year":"1996","unstructured":"Teofoli P, Mancini A, Lotti T (1996) Cyclosporine A inhibits tPA mRNA transcription in A431 cell line. Skin Pharmacol 9(2):137\u2013140","journal-title":"Skin Pharmacol"},{"key":"1738_CR67","first-page":"18","volume":"85","author":"VA Tkachuk","year":"2013","unstructured":"Tkachuk VA, Plekhanova OS, Beloglazova IB, Parfenova EV (2013) A role of multi-domain structure of urokinase in regulating vascular growth and remodeling. Ukr Biokhim Zh 85:18\u201345","journal-title":"Ukr Biokhim Zh"},{"key":"1738_CR68","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1523-1747.ep12462121","volume":"90","author":"R Tsuboi","year":"1988","unstructured":"Tsuboi R, Yamaguchi T, Kurita Y, Nakao H, Ishihara K (1988) Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis. J Investig Dermatol 90:869\u2013872","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1738_CR69","first-page":"45","volume":"7","author":"WD Tutrone","year":"2004","unstructured":"Tutrone WD, Saini R, Weinberg JM (2004) Biological therapy for psoriasis; an overview of infliximab, etanercept, efalizumab and alefacept. I Drugs 7(1):45\u201349","journal-title":"I Drugs"},{"issue":"1","key":"1738_CR70","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0268-9499(94)90715-3","volume":"8","author":"J-D Vassalli","year":"1994","unstructured":"Vassalli J-D (1994) The urokinase receptor. Fibrinolysis 8(1):172\u2013181","journal-title":"Fibrinolysis"},{"issue":"12","key":"1738_CR71","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1158\/1535-7163.MCT-13-0204","volume":"12","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O\u2019Halloran TV, Lengyel E (2013) Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther 12(12):2628\u20132639","journal-title":"Mol Cancer Ther"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-017-1738-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-017-1738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-017-1738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T08:03:46Z","timestamp":1569053026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-017-1738-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s00403-017-1738-z","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]}}}